These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1827280)

  • 1. Polymorphic oxidation of debrisoquine in lung cancer patients.
    Benítez J; Ladero JM; Jara C; Carrillo JA; Cobaleda J; Llerena A; Vargas E; Muñoz JJ
    Eur J Cancer; 1991; 27(2):158-61. PubMed ID: 1827280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.
    Ladero JM; Benítez J; González JF; Vargas E; Díaz-Rubio M
    Eur J Clin Pharmacol; 1991; 40(5):525-7. PubMed ID: 1884729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic oxidation of debrisoquine in women with breast cancer.
    Ladero JM; Benítez J; Jara C; Llerena A; Valdivielso MJ; Muñoz JJ; Vargas E
    Oncology; 1991; 48(2):107-10. PubMed ID: 1997931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.
    Ayesh R; Idle JR; Ritchie JC; Crothers MJ; Hetzel MR
    Nature; 1984 Nov 8-14; 312(5990):169-70. PubMed ID: 6504125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
    Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquine oxidation polymorphism in patients with chronic inflammatory bowel disease.
    Ladero JM; Benítez J; Serrano M; García-Paredes J; Diaz-Rubio M
    Ann Med; 1995 Oct; 27(5):555-8. PubMed ID: 8541031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic oxidation of debrisoquine in bladder cancer.
    Benítez J; Ladero JM; Fernández-Gundín MJ; Llerena A; Cobaleda J; Martínez C; Muñoz JJ; Vargas E; Prados J; González-Rozas F
    Ann Med; 1990 Jun; 22(3):157-60. PubMed ID: 2393550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimer's disease.
    Benítez J; Barquero MS; Coria F; Molina JA; Jiménez-Jiménez FJ; Ladero JM
    J Neurol Sci; 1993 Jul; 117(1-2):8-11. PubMed ID: 8410072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis.
    Ritchie JC; Idle JR
    IARC Sci Publ; 1982; (39):381-94. PubMed ID: 7152615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Eur J Clin Pharmacol; 1997; 51(5):389-93. PubMed ID: 9049580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
    Lennard MS
    Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
    Alván G; Bechtel P; Iselius L; Gundert-Remy U
    Eur J Clin Pharmacol; 1990; 39(6):533-7. PubMed ID: 2151318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.
    Duche JC; Joanne C; Barre J; de Cremoux H; Dalphin JC; Depierre A; Brochard P; Tillement JP; Bechtel P
    Br J Clin Pharmacol; 1991 May; 31(5):533-6. PubMed ID: 1888620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
    Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL
    J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?
    Horsmans Y; Desager JP; Harvengt C
    Biomed Pharmacother; 1991; 45(8):359-62. PubMed ID: 1773024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.